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Abstract
Introduction: Women experience pain during medical abortion, yet optimal pain 
management remains unclear. We studied the pain experience and need of analge-
sics during early medical abortion (≤63 days of gestation) among teenage and adult 
women. We also assessed predictive factors of severe pain.
Material and methods: We recruited 140 primigravid women: 60 teenagers and 80 
adult women aged between 25 and 35 years old. The group of teenagers included 19 
women under the age of 18 years old (minors). The abortion was performed with mife-
pristone (200 mg) followed by vaginal misoprostol (800 μg), mainly self-administered 
at home for adults. Minors were hospitalized during misoprostol administration. Pain 
medication consisted of ibuprofen 600 mg and paracetamol 1000 mg, first doses 
taken simultaneously with misoprostol and repeated, if needed, up to three times 
daily. Additional opiates (mainly tramadol or oxycodone) were administered at hos-
pital if needed. Pain was measured using the visual analogue scale (VAS, 0-100 mm).
Results: The maximal pain VAS (median, interquartile range) was 75 (54-91). Of all the 
women, 57.7% experienced severe pain (VAS ≥70) during abortion care and 93.5% 
of women needed additional analgesics in addition to prophylactic pain medication. 
Teenagers needed additional analgesics more often than adults (5 [3-8] vs 3 [2-6] 
times, P = .021); 38.0% of all teenagers (64.7% of the minors) received additional opi-
ates compared with 7.9% in adult women. Severe pain (VAS ≥70) was associated with 
history of dysmenorrhea (adjusted odds ratio [OR] 2.60 [95% confidence interval [CI] 
1.21-5.59, P = .014]), anxiety at baseline (2.64 [1.03-6.77], P = .044) and emesis dur-
ing abortion (5.24 [2.38-11.57], P < .001). Hospital administration of misoprostol did 
not lower the risk for severe pain experience (OR 0.84 [95% CI 0.34-2.05], P = .694). 
Satisfaction with care was high in study population (median VAS 91 [interquartile 
range 79-97]) and was not associated with the use of narcotic analgesic or place of 
misoprostol administration.
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1  | INTRODUC TION
Abortion methods have rapidly changed from surgical to medi-
cal in several countries. In 2017, the medical method by means 
of mifepristone followed by misoprostol was used in 75%-97% of 
all abortions in the Nordic countries and in Scotland.1,2 Moreover, 
medical abortion is as effective and safe for adolescents as for 
adult women.3
Most patients undergoing medical abortion experience abdomi-
nal pain and, in every fourth woman, even severe pain.3-7 Predictive 
factors for severe pain include young age, nulligravidity, advanced 
gestational age, anxiety and history of dysmenorrhea.4-6,8,9 However, 
little is known on pain experience among teenage women undergo-
ing medical abortion. A history of abortion might also be a risk factor 
for severe pain, even if it has no effect on the need for analgesics.9,10 
Still, fear of pain might be one reason women prefer surgical abor-
tion over the medical one.11,12
The overall need for analgesics during medical abortion in 
early pregnancy has been reported to vary between 68 and 91%, 
and 2-29% of women need additional narcotic analgesics.5,7,13,14 
Nonsteroidal anti-inflammatory drugs are widely used and they 
do not decrease the efficacy of medical abortion.10,15,16 Ibuprofen 
and paracetamol both decrease the pain score during early medi-
cal abortion, ibuprofen being more effective.10 Furthermore, pro-
phylactic administration of nonsteroidal anti-inflammatory drugs 
reduces the need for additional pain medication and opiates.15-17 
Yet, regular use of ibuprofen during medical abortion only in-
creases the number of tablets used without any effect on the pain 
experience.4,15,17
Pain and the use of analgesics are often poorly reported in stud-
ies on medical abortion and variation of medical methods makes 
the comparison of pain experience difficult.18,19 Though pain is 
a known adverse effect of medical abortion, guidelines on pain 
management are limited. The World Health Organization (WHO), 
the International Federation of Gynecology and Obstetrics (FIGO), 
the American College of Obstetricians and Gynecologists (ACOG), 
and the Royal College of Obstetricians and Gynaecologists (RCOG) 
recommend that women undergoing medical abortion should be 
routinely offered analgesics but only the use of nonsteroidal an-
ti-inflammatory drugs is mentioned.20-23 A recent survey showed 
that there is a large variation in the analgesics used among abor-
tion providers.24
In this prospective study, we assessed the pain experience, the 
need for analgesics, and adequacy of the combination of ibupro-
fen and paracetamol during medical abortion in early pregnancy. 
All these factors were evaluated among teenage and adult women. 
Also, we studied the predictive factors of severe pain and the need 
for additional pain medication, and assessed the acceptability of 
medical abortion and patient satisfaction in relation to pain experi-
enced in the study cohort.
2  | MATERIAL AND METHODS
This prospective study was conducted at the Department of 
Obstetrics and Gynecology of the Helsinki University Hospital 
between 7 March 2016 and 31 August 2018. Women requesting 
early medical abortion (up to 63 days of amenorrhea) were invited 
to participate in the study. The inclusion criteria were age between 
15-19 or 25-35 years, first singleton pregnancy, and no allergy for 
analgesics used in the study. Women seeking abortion due to fetal 
abnormalities or maternal health conditions were excluded, as were 
women with a history of opioid addiction. Women volunteering for 
the study received written and verbal information on the study and 
signed an informed consent form. All women attending a follow-up 
were included in the analysis. Furthermore, we made analysis of mi-
nors (aged 16-17 years) and late teens (aged 18-19 years) separately 
for some of the results.
Medical abortion was carried out according to the Finnish na-
tional guideline as follows: mifepristone (200 mg) was adminis-
tered orally at the outpatient clinic (day 1) followed by misoprostol 
(0.8 mg) administered vaginally (or orally in cases of heavy bleeding) 
at 48-72 hours later (day 3 or 4). Patients ≥18 years old primarily 
Conclusions: Pain intensity was high both in teenage and adult women undergoing 
medical abortion, yet satisfaction on care was high. More effective analgesics than 
ibuprofen and paracetamol should be offered to all women undergoing early medi-
cal abortion, especially to those with history of dysmenorrhea. Also, routine use of 
antiemetics might be advisable.
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Key message
More than half of women experience severe pain during 
medical abortion. Severe pain was associated with history 
of dysmenorrhea, anxiety at baseline and emesis during 
abortion. Prophylactic use of ibuprofein and paracetamol 
alone is not adequate for pain management.
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self-administered misoprostol at home. Minors (<18 years old) were 
managed for the first 4-6 hours after misoprostol administration at 
the outpatient clinic according to local guidelines.
Clinical examination and determination of the duration and 
status of the pregnancy by vaginal ultrasound were performed 
at the outpatient clinic. Women participating in the study filled 
out a questionnaire, including background information and stan-
dardized questionnaire on anxiety and depression [General Health 
Questionnaire 12 (GHQ–12)]. We used GHQ scoring and a thresh-
old limit of 6/12 as indicator of anxiety when analyzing the GHQ–
12 questionnaire.25
Abortion-related pain was recorded in a paper diary in which 
women were asked to estimate the intensity of pain and emesis 
every time additional analgesics were needed and to record the use 
of analgesics. Follow-up visits were scheduled in 2-4 weeks, during 
which the outcome of abortion was verified by means of ultrasound, 
and women completed questionnaires on satisfaction, memory of 
pain, adequacy of the analgesics used, and willingness to choose 
medical abortion again if needed.
Intensity of pain, emesis during the current pregnancy and pa-
tient satisfaction were measured using a 0- to 100-mm visual ana-
logue scale (VAS), where patients mark the point on a 100 mm line, 
which describes best the intensity of her pain, emesis, or satisfaction 
(0 meaning no pain or emesis, and 100 as the worst imaginable pain 
or emesis). Regarding the intensity of pain, VAS 0-40 was considered 
mild or tolerable pain, and VAS ≥70 severe pain.26 We assumed that 
pain was tolerable (VAS ≤40) among women who returned an empty 
pain diary due to no need for additional pain medication. Reported 
use of pain medication during menses was used as an indicator of 
history of dysmenorrhea.
Analgesics used in this study were 600 mg of ibuprofen and 
1000 mg of paracetamol (acetaminophen), both administered 
orally. This is according to local practice. First, prophylactic doses 
of both analgesics were to be taken simultaneously with misopros-
tol and repeated later whenever needed, both up to three times 
daily. All patients were provided with 10 tablets of both anal-
gesics, but not narcotic analgesics for home use. Narcotic anal-
gesics were mainly given at hospital outpatient clinic if needed. 
Administration route and doses (oral or intramuscular) were de-
cided case by case at hospital, and opiates used were tramadol or 
oxycodone. None of women was provided narcotics for home use 
by the investigators.
The main outcome measures were pain during medical abortion 
and the need for analgesics. Secondary outcome measures were em-
esis and satisfaction with the treatment. We determined the need 
for analgesic by counting times and types of analgesics taken during 
medical abortion. We assessed predictive factors for severe pain 
experience.
2.1 | Statistical analyses
Sample size was that of convenience and was based on the expected 
number of induced abortions among teenage women over 1 year. It 
was assumed that half of all women eligible for the study would be 
willing to participate. Therefore, the aim was to recruit at least 60 
teenagers and a similar group of adults as a reference group.
We used IBM SPSS version 25 for Mac (IBM Corp.) for analyses. 
Comparisons were performed using nonparametric tests, Pearson’s 
chi-squared test, and Mann-Whitney U test as appropriate. We used 
logistic regression for calculating odds ratios. All statistical tests 
were two-tailed. A P-value <.05 was considered to be statistically 
significant.
2.2 | Ethical approval
We obtained an approval from the ethics committee of Hospital sys-
tem of Helsinki and Uusimaa (HUS320/13/03/03/2015) as well as 
from the Finnish Medical Agency. The EudraCT registration number 
of the study is 2015-005657-12, and that of www.clini caltr ials.gov 
registration is NCT02678897.
3  | RESULTS
A total of 140 women were recruited. Altogether, eight (5.7%) 
women failed to attend the follow-up visit and were excluded 
from the analysis (Figure 1). In all, 132 women (56 teenagers [19 
minors] and 76 adult women) were included in the analysis. Data 
F I G U R E  1   Study flow [Color figure can 
be viewed at wileyonlinelibrary.com]
 
Altogether 140 women were recruited in the 
study:  
1. 60 teenagers (aged 15-19 years old) 
2. 80 adult women (aged 25-35 years old)  
Exclusion; 5.7% of recruited women: 
-1 teenager did not meet the inclusion 
criteria (longer duration of gestatio) 
-3 teenagers and 4 adults did not attend to a 
follow-up visit 
Women included in analysis 
1. 56 teenagers 
2. 76 adult women 
3/1 patients were missing backround 
questionnaires (2 of teenagers missed also 
pain diary) 
6/3 patients did not return the pain diary 
0/4 patients returned an empty pain diary as 
they did not have a need for additional 
analgesics 
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were partly missing for seven (12.5%) teenagers and four (5.3%) 
adults. However, there was no difference in the background char-
acteristics between the women replying to all questionnaires and 
those with some missing data. Thus, the incidence of missing data 
was assumed to be random and these women were included in the 
final analyses.
The teenage and adult women were similar in many aspects 
(Table 1). Teenagers smoked more often (47.3% vs 30.3%, P = .047) 
and were more often in a relationship than adult women were (87.8% 
vs 50.7%, P < .001). Altogether, 60.3% of all women reported analge-
sic use for menstrual pain, the proportion being similar among teen-
agers and adult women (67.3% vs 55.4%, P = .179). The proportion of 
women with a history of psychiatric diagnoses was indistinguishable 
between the two cohorts (teenagers 8.9% vs adults 9.2%, P = .956).
The maximal pain VAS during abortion (median, interquartile 
range) was 75 (54-91) in the study population and was similar 
in both subgroups (teenagers 79 [63-93] and adults 73 [50-90], 
P = .107). Moreover 57.7% of all women experienced severe pain 
(VAS ≥70) during abortion care (Figure 2). Only 13.8% of all women 
reported pain as tolerable during abortion (VAS <40). The most in-
tensive pain was reported at 2.3 (1.1-5.0) and 3.4 (1.1-6.0) hours 
after misoprostol administration (P = .451) in teenage and adult 
groups, respectively. The memory of pain, asked at the follow-up 
visit, correlated with maximal pain VAS reported at the time of 
abortion being 73 in all women (78 [62-90] in teenagers and 70 
[46-83] in adult women, P = .052). Table 2 presents the outcome 










Age (years) 26 (19-29) 19 (17-19) 28 (27-31) <.001
BMI (kg/m2)a  22 (21-24) 22 (20-25) 22 (21-24) .335
Duration of gestation (days) 48 (44-54) 50 (45-57) 48 (44-53) .074
Reported ovulation pain 
(VAS)b 
8 (0-31) 11 (1-38) 6 (0-30) .301
Reported menstrual pain 
(VAS)b 
36 (11-64) 40 (14-63) 33 (10-64) .679
Emesis in the current 
pregnancy (VAS)b 
32 (8-61) 42 (14-69) 26 (0-58) .089
Anxiety at the time of 
abortion (GHQ-12)c 
3 (1-6) 3 (1-6) 3 (1-7) .473
Proportion of women 
having GHQ score ≥6, n (%)
31 (26.5) 13 (26.0) 18 (26.9) .916
aData on weight are missing from three teenagers and eight adult women. 
bBackground questionnaires missing from three teenagers and one adult woman. 
cAnxiety questionnaire was missing or empty in six teenagers and nine adult women. 
TA B L E  1   Descriptive data of all women 
comparing teenagers and adult women. 
Results are median (IQR) unless stated 
otherwise
F I G U R E  2   Proportions of women experiencing different categories of pain [Color figure can be viewed at wileyonlinelibrary.com]
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A total of 38.7% of women reported the onset of pain before 
misoprostol intake. The duration of pain (defined as the last recorded 
VAS measurement after misoprostol administration) was longer 
among teenagers (52.3 [23.4-99.2] hours) than adult women (24.4 
[5.3-68.3] hours, P = .007). Only 39.3% of all women did not report 
pain beyond 24 hours after misoprostol administration, the count 
being higher among adult women (48.0% vs 26.5% in teenagers, 
P = .018). Conversely, 29.5% of women reported pain still continuing 
72 hours after misoprostol administration, whereas 11% of the adult 
women and none of teenagers reported pain only before misoprostol 
administration.
Most teenagers and adult women needed analgesics (96.0% 
vs 91.8%, P = .351) in addition to the prophylactic pain medication 
(Table 2). The teenagers needed analgesics more often (5.0 [3.0-8.3] 
vs 3 [2.0-5.5] times, P = .007) and were also more likely to receive 
additional narcotic analgesics compared with adult women (OR 6.84 
[95% CI 2.49-18.82], P < .001). Altogether, 16.3% of women received 
additional narcotic analgesics; the proportion among minor women 
was as high as 64.7%. Two teenagers and three adult women reported 
use of their own tablets containing a combination of paracetamol and 
codeine.
Misoprostol was more often administered at hospital to teen-
agers than to adult women (n = 24, 42.9% vs n = 2; 2.6%, P < .001) 
due to local guidelines. Also, hospital administration of misopros-
tol was associated with higher use of additional narcotic analgesics 
(OR [adjusted for age group] 12.92 [95% CI 3.69-45.27], P < .001). 
Neither the proportion of women experiencing severe pain (VAS 
≥70, 54.2% vs 61.1%, P = .539) nor the proportion reporting pain 
as tolerable (VAS <40, 8.3% vs 15.2%, P = .387) differed between 
the women managed at the hospital compared with at home. Both 
women treated at home and at hospital were very satisfied with 
the care (median VAS 91 [interquartile range 78-97] vs 92 [86-98], 
P = .193).
The risk factors of severe pain (VAS ≥70) during medical abor-
tion were evaluated in all women (Table 3). A history of dysmen-
orrhea was associated with severe pain (adjusted OR 2.60 [95% CI 
1.21-5.59], P = .014), as were reported emesis at any time during 
medical abortion (adjusted OR 5.24 [95% CI 2.38-11.57], P < .001) 





Severe pain VAS ≥70a  34 (68.0)
- Minors 11 (64.7)
- 18- to 19-year-olds 
23 (69.7)
37 (50.7) .056
Mild/tolerable pain VAS ≤40a  1 (2.0) 16 (21.9) .002
Need of additional analgesicsa  48 (96.0) 67 (91.8) .351
Given additional narcotic analgesicsa  19 (38.0)
- Minors 11 (64.7)




At hospital 24 (42.9) 2 (2.6)
At home 32 (57.1) 74 (97.4) <.001
Additional narcotics used:
Misoprostol administered at home 3 (10.7) 2 (2.8)
vs in hospitala,b  14 (63.6) (P < .001) 1 (50) (P = .001)
Onset of pain before misoprostol 
administrationa 
19 (38.8) 32 (45.8) .452
Reported emesis during medical 
abortion at any timea 
34 (68.0) 35 (47.9) .028
Satisfaction on care VAS (median, IQR) 91.0 (79.5-96.8) 92.0 (78.3-97.5) .572
Analgesia reported as adequate (Yes, 
%)
43 (81.1) 51 (67.1) .078
Would you choose medical abortion 
again? (Yes, %)
49 (89.1)
- Minors 18 (94.7)
- 18- to 19-year-olds 
31 (86.1)
70 (92.1) .555
aPain diary was missing from six teenagers and three adult women and thus the information of 
these was missing. 
bNarcotic analgesics were mainly given at hospital orally or intramuscularly. Two teenagers and 
three adult women reported use of their own tablets containing combination of paracetamol and 
codeine. 
TA B L E  2   Comparison between 
teenage and adult women in various 
outcome measures. The results are n (%) 
unless stated otherwise
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and anxiety (adjusted OR 2.64 [95% CI 1.03-6.77], P = .044). A his-
tory of dysmenorrhea was associated with a higher number of an-
algesics needed (5 [3-9] vs 2 [1-5], P < .001). The odds of reporting 
emesis were higher if narcotic analgesics were used (OR 3.04 [95% 
CI 1.12-8.26], P = .029).
The satisfaction with care was high among all women (median 
VAS 91 [interquartile range 79-97]) and was similar among teenag-
ers and adult women (Table 2). Administration vs no administration 
of narcotic analgesics (VAS 96 [90-99] vs 91 [78-97], P = .060) or 
the place of misoprostol administration (hospital VAS 92 [86-98] 
vs home 91 [78-97], P = .211) had no effect on satisfaction. Pain 
medication was assessed as adequate by 72.9% of all women, and 
90.2% would choose medical abortion again in case of new abortion. 
Satisfaction with care did not differ significantly whether pain med-
ication was assessed as adequate or not (VAS 92.0 [82.8 vs 97.0] vs 
82.0 [68.0-97.0], P = .069).
4  | DISCUSSION
Maximal pain during early medical abortion is high, among both 
teenagers and adults. However, the maximal pain is less often mild 
or tolerable (VAS ≤40) among teenagers. The majority of women 
needed pain medication in addition to prophylactic ibuprofen and 
paracetamol, and most of the teenagers managed at the outpatient 
clinic received narcotic analgesics. Severe pain was associated with 
emesis during medical abortion, anxiety and reported history of 
dysmenorrhea. Nevertheless, the great majority of the women were 
satisfied with the treatment, and more than three of five evaluated 
pain medication as adequate.
Our study confirms that a history of dysmenorrhea is a predictive 
factor for severe pain during medical abortion.4,8,15 We found no dif-
ference in the pain intensity between teenagers and adult women, 
but the consumption of analgesics was higher among teenagers, 
Variable
Pain max. VAS ≥70
OR (95% CI) P value
Pain max. VAS ≥70




Teens 2.07 (0.98-4.38) .058
Adults 1
Dysmenorrheab  2.74 (1.29-5.84) .009 2.60 (1.21-5.59) .014
No dysmenorrhea 1
BMI
<25 kg/m2 1 .360
>25 kg/m2 1.56 (0.60-4.06)
Anxiety at baseline
Yes 2.50 (0.99-6.32) .053 2.64 (1.03-6.77) .044
No 1
Smoking
Yes 0.72 (0.34-1.52) .393
No 1
Relationship status
Single 0.62 (0.29-1.32) .211
In relationship 1
Emesis during abortion




No 9.00 (2.92-27.71) <.001 12.53 (3.86-40.73) <.001
Yes 1
Place of misoprostol 
administration
Hospital 0.84 (0.34-2.05) .694
Home 1
aAdjusted for age group. 
bThat is, reported use of pain medication for menstrual pain. Reported menstrual pain was 
significantly higher in women who reported use of pain medication during menses (VAS 57.0 [34.3-
69.8]) than in women with no such use (VAS 10.0 [0.0-23.3], P < .001). 
TA B L E  3   Predictors and associated 
factors of severe pain experience (pain 
VAS max. ≥70) in all women. Results of the 
regression analyses
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which indicates that young age is also associated with experiencing 
stronger pain. One-third of women reported pain beyond 72 hours 
after misoprostol administration. Also, anxiety at baseline and re-
ported emesis were associated with severe pain. The occurrence 
of emesis is likely to be partly explained by the use of narcotic an-
algesics. Due to difficulty in predicting the occurrence of emesis, 
we propose that all women undergoing medical abortion should be 
routinely administered antiemetic medication, especially if narcotic 
analgesics are needed.
The pain observed in the present study was more intense than 
that seen in most previous studies in medical abortion regimens 
containing various combinations of mifepristone and misopros-
tol.5,8 Similarly, the onset of pain before misoprostol administra-
tion was more frequent (38.7%) than reported previously (11%).27 
As the most intense pain often occurs soon after misoprostol in-
take, there is a place for prophylactic pain medication to be used 
at the time of misoprostol administration as recommended by the 
WHO and RCOG guidelines on abortion care.20,21 Moreover, the 
wide variation in the duration of pain calls for individualization of 
pain management.
Surprisingly, more than three of five women assessed the com-
bination of ibuprofen and paracetamol as adequate. The higher use 
of additional narcotic analgesics among teenagers is likely to be due 
to their hospitalization during misoprostol administration. The hos-
pital care during misoprostol administration was associated with 
more frequent use of narcotic analgesics but not with severe pain 
experience. As the reported pain was often severe, we assume that 
the use of narcotic analgesics, especially among teenagers, was well 
justified.
The satisfaction with care was high and 9 of 10 women would 
choose medical abortion again. Factors affecting patient satisfaction 
are diverse. Neither place of misoprostol administration nor use of 
narcotic analgesics seems to have an effect on patient satisfaction. 
We assume that good patient satisfaction is likely to be due to wom-
en’s trust in the care, interaction between patients and healthcare 
providers and clear, understandable instructions. It is also notable 
that the study patients had an additional follow-up visit at the out-
patient clinic, which might have had a positive effect on the overall 
satisfaction.
Studies on medical abortion among teenagers are scarce, which 
makes our study important. Local practice, where minors are hospi-
talized at the time of misoprostol intake and adult women are not, 
limits our study for several reasons. First, this had an effect on fre-
quency of narcotic use and might also have had an influence on over-
all pain medication use, as women probably had easier access to pain 
medication in the hospital care. Still, women were not provided any 
narcotic analgesic for home use when misoprostol was administered 
at home. Second, it might have had an effect on patient selection. 
This must be kept in mind when comparing results of teenagers and 
adult women in our study. Also, our relatively small sample size lim-
its the power of our study. The adult comparison group consisted 
of women aged 25-35 years. This was done for the sake of clarity 
but may also be seen as a shortcoming. The results are mainly based 
on self-reporting using a study diary, and due to this we might have 
overlooked some information. Additionally, the period of recruit-
ment took longer than expected, probably due in part to decreasing 
abortion rates, especially among teenagers.1
5  | CONCLUSION
Most women experience severe pain during medical abortion. As 
only one of five adults and almost none of the teenagers reported 
pain as mild or tolerable, it is obvious that the combination of ibupro-
fen and paracetamol used in our study was not sufficient. A history 
of dysmenorrhea and emesis during abortion care were risk factors 
for severe pain. As most women experienced the worst pain within a 
few hours after misoprostol administration, administering pain med-
ication at the time of misoprostol is likely to be valuable. Providing 
women with a small package (eg 10 tablets) of a weak opioid such 
as tramadol to be administered at home might be advisable, espe-
cially for young women and women with a history of dysmenorrhea. 
Furthermore, providing antiemetic medication might be valuable. 
Pain management during medical abortion needs to be improved 
further, and studies on optimizing pain medication are needed.
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